Request Trial
8 December 2016Americas

CRISPR dispute likely to continue in federal courts

Following the CRISPR/Cas9 patent hearing on December 6 between The Broad Institute and University of California, Berkeley (UCB), it is very unlikely that the case will end at the US Patent and Trademark Office (USPTO), according to one lawyer.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Novartis win blocks generics relitigating $7.8bn heart drug patent
22 January 2026   A district court judge shuts down a Novartis rival from reopening validity and infringement arguments over an Entresto patent.
Americas
Rooted rights: Lessons from plant patent infringement and invalidity cases
22 January 2026   From public use and foreign sales to the challenges of proving infringement, plant patents present unique legal opportunities—and pitfalls—for the agricultural industry, explain Bree Vculek, Gaby Longsworth, and Robert Millonig of Sterne Kessler.
Americas
Skinny labels, big stakes: SCOTUS lines up the case of the year
21 January 2026   The court’s review of a high-profile dispute could offer clarity on a grey area for pharma companies and generic drug makers, but also prompt fresh questions.


Editor's picks

Final call: Who are the world’s best in-house counsel?
Europe
Final call: Who are the world’s best in-house counsel?
16 January 2026

Editor's picks

Europe
Final call: Who are the world’s best in-house counsel?
16 January 2026

More features

Novartis win blocks generics relitigating $7.8bn heart drug patent
Leading the arena: WIPR identifies the top US trade secrets specialists of 2025
Rooted rights: Lessons from plant patent infringement and invalidity cases
Cadwalader global head among trio moving to Orrick
Skinny labels, big stakes: SCOTUS lines up the case of the year
Chinese biotech strikes billion dollar deal in nextgen cancer race
$5.4bn medtech leader fails to bury a rival's patent
Senior four-partner team leaves A&O Shearman